Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Nina S. Kjellson Sells 1,076 Shares of Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Nina S. Kjellson sold 1,076 shares of the company’s stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $17.01, for a total value of $18,302.76. Following the completion of the sale, the director now owns 458,390 shares of the company’s stock, valued at $7,797,213.90. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Tyra Biosciences Stock Performance

NASDAQ TYRA opened at $17.12 on Thursday. The stock has a market cap of $904.11 million, a price-to-earnings ratio of -10.13 and a beta of 1.08. The business has a 50 day simple moving average of $22.09 and a 200 day simple moving average of $19.96. Tyra Biosciences, Inc. has a 52-week low of $10.60 and a 52-week high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.09. On average, analysts predict that Tyra Biosciences, Inc. will post -1.53 EPS for the current year.

Institutional Investors Weigh In On Tyra Biosciences

Institutional investors have recently added to or reduced their stakes in the stock. Oppenheimer & Co. Inc. acquired a new stake in shares of Tyra Biosciences in the 1st quarter valued at about $977,000. Vanguard Group Inc. grew its holdings in shares of Tyra Biosciences by 18.6% during the first quarter. Vanguard Group Inc. now owns 899,800 shares of the company’s stock worth $14,757,000 after buying an additional 140,833 shares in the last quarter. American Century Companies Inc. raised its position in Tyra Biosciences by 582.9% in the 2nd quarter. American Century Companies Inc. now owns 170,283 shares of the company’s stock valued at $2,723,000 after buying an additional 145,346 shares during the last quarter. Perceptive Advisors LLC lifted its stake in Tyra Biosciences by 50.5% in the 2nd quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company’s stock valued at $16,108,000 after acquiring an additional 338,208 shares in the last quarter. Finally, Ensign Peak Advisors Inc acquired a new position in Tyra Biosciences during the 2nd quarter worth approximately $3,047,000. 84.14% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on TYRA. Piper Sandler assumed coverage on Tyra Biosciences in a research report on Thursday, August 15th. They set an “overweight” rating and a $33.00 target price for the company. Wedbush restated an “outperform” rating and set a $28.00 price objective on shares of Tyra Biosciences in a report on Friday, October 25th. Bank of America upgraded shares of Tyra Biosciences from a “neutral” rating to a “buy” rating and increased their target price for the stock from $22.00 to $31.00 in a report on Friday, October 18th. HC Wainwright boosted their price target on shares of Tyra Biosciences from $30.00 to $32.00 and gave the company a “buy” rating in a report on Monday, October 28th. Finally, Oppenheimer upped their price objective on shares of Tyra Biosciences from $25.00 to $33.00 and gave the company an “outperform” rating in a research report on Thursday, September 19th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $31.40.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.